by Gram-positive Bacterial Infections Market: Snapshot
The global gram-positive bacterial infections market is expected to demonstrate upward curve of growth during the forecast period of 2018 to 2026. Some of the key reasons for this growth are significant growth in patients living with gram-positive bacterial infections and a swift increase in antibacterial resistance. Gram-positive bacterial infection drugs are effective option in the treatment of various infections including sinusitis, MRSA infections, and pneumonia.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111961
Gram-positive bacteria are considered as a key class of bacteria responsible for causing numerous infections in humans. They are known for retaining gram stain. Under microscope, they are observed as violet purple colored stains. Gram-positive bacterial infection drugs use diverse mechanisms including protein biosynthesis inhibition, cell wall synthesis inhibition, and DNA replication inhibition.
Vendors working in the global gram-positive bacterial infections market are heavily investing in research activities. This move is helping them to offer superior quality drugs. As a result, the market for gram-positive bacterial infections is witnessing stupendous expansion avenues in the upcoming period. Apart from this, government bodies of many countries across the world are taking initiatives to support in finding out advanced bacterial infection treatment. For this purpose, they are backing various research and development activities. This is working as a driver for the global gram-positive bacterial infections market.
Several enterprises from the global gram-positive bacterial infections market are executing various strategies such as collaborations and partnerships. Key motive behind these moves is regional expansion. In addition to this, increased number of mergers and acquisitions connotes that the global gram-positive bacterial infections market will grow at rapid pace during upcoming years.
The gram-positive bacterial infections market is expected to experience significant growth avenues in North America. Remarkable increase in the number of people living with bacterial infections, presence of key players, and improved diagnosis and treatment rate are some of the key reasons fueling the market growth in the region.
Gram-positive Bacterial Infections Market – Snapshot
Gram-positive bacterial infection drugs act against gram-positive bacterial infections such as MRSA infections, sinusitis, and pneumonia. Gram-positive bacteria are those class of bacteria that retain gram stain and hence, are observed as violet purple colored stains when observed under the microscope. They are a major class of bacteria that cause various infections in humans. These drugs act by various mechanisms such as inhibition of cell wall synthesis, inhibition of protein biosynthesis, and inhibition of DNA replication. The global gram-positive bacterial infections market was valued at around US $ 51,450 Mn in 2017. It is expected to expand at a CAGR of 1.5% from 2018 to 2026. The market for gram-positive bacterial infections is expanding significantly, owing to an increase in the number of cases of gram-positive bacterial infections and a rapid rise in antibacterial resistance. Increased government initiatives and funding for R&D activities & newer bacterial infection treatment and infection control in healthcare settings is also a key factors driving the market globally.
gram-positive-bacterial-infections-market.jpg
The gram-positive bacterial infections market has been segmented based on drug type, disease, route of administration, distribution channel, and region. Based on drug type, the global market is classified into antibiotic, antifungal, and others. The antibiotic segment has been further sub-segmented into B-lactam, quinolones, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, and others. The antibiotic segment dominated the global market and is expected to maintain its position during the forecast period owing to better efficacy in treatment of wide spectrum of bacterial infections and development of novel approaches for new antibiotics. The others segment, which includes antitoxins, corticosteroids, supplements, anti-dialectic, calcium, probiotics, is expected to expand at a higher CAGR during the forecast period owing to the popularity of combination drugs prescribed for patients who are more prone to the adverse effects of single antibiotic prescription. Based on disease, the global gram-positive bacterial infections market has been divided into MRSA, pneumonia, sepsis, sinusitis, cellulitis, otitis, pharyngitis, impetigo, and others. The sinusitis segment is dominant owing to the rise in prevalence of sinusitis and increased usage of antibiotics for this infection. The otitis segment is projected to expand at a higher CAGR during the forecast period due to a rise in the prevalence of otitis media and the efficacy and safety of antibacterial agents to cure the infection. In terms of route of administration, the global gram-positive bacterial infections market has been classified into enteral, parenteral and others. The enteral segment dominated the market global market. Patient preference, ease of administration and ability to achieve desired therapeutic concentration are some factors driving the enteral segment. Based on distribution channel, the global gram-positive bacterial infections market has been segregated into hospital pharmacies, drug stores and retail pharmacies, and others. The others segment, which consist of online pharmacies and mail pharmacies, is projected to expand at a notably higher CAGR. This expanded CAGR is attributed to better discounted rates on drug purchase and convenience offered by online pharmacies.
In terms of region, the global gram-positive bacterial infections market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global gram-positive bacterial infections market in 2017, owing to a rise in the prevalence of bacterial infections, better diagnosis and treatment rate, and presence of major players in the region. Asia Pacific is a lucrative market for gram-positive bacterial infections, and the market is estimated to expand at a prominent CAGR during the forecast period due to larger patient pool and rising number of infected cases in the region.
Key players operating in the global Gram-Positive Bacterial Infections market include Bayer AG, Pfizer, Inc., Sanofi, GlaxoSmithkline plc (GSK), Merck & Co., Inc., AstraZeneca, Theravance Biopharma, Bristol-Myers Squibb Company, Novartis AG, and Allergan plc.
Newer Options for Infection Control Propels Growth in Gram-Positive Bacterial Infections Market
Manufacturers and researchers in the global gram-positive bacterial infections market are looking forward to developing newer treatment and infection control solutions. Increasing number of research studies, clinical trials, and drug discovery processes are being undertaken by industry players to meet the rising demand for cost effective and fast acting antibiotic and antibacterial drug formulations. For example, a company called ‘Basilea Pharmaceutica’ announced the positive results for the phase 3 target study of their antibiotic drug product called ‘Ceftobiprole’. This drug is designed to treat acute bacterial skin disorders and skin structure infections. Furthermore, Bayer Global launched an antibiotic natural dipeptide known as ‘TAN 1057 AB’ that shows promising antibacterial activity against the staphylococci, including staphylococcus aureus that resists methicillin.
Increased government participation in supporting the ongoing research and development activities is anticipated to act favorably for the growing gram-positive bacterial infections market. Furthermore, factors such as increasing awareness among global population regarding the severe effects of infectious diseases and rapidly increasing technological strides in antibacterial resistance are supplementing the increased demand in global gram-positive bacterial infections market. However, there are some concerning factors that can impede the market growth in coming years. These factors include high cost of treatment, ignorance and lack of awareness regarding the proper identification of symptoms, and stringent government regulations. These factors, along with high cost associated with research and development processes for designing and developing newer drug therapies can hinder the growth of global gram-positive bacterial infections market in near future. Like every other industry, the global gram-positive bacterial infections market was also deeply impacted by the global COVID-19 pandemic. As of yet, there is no drug or therapeutic product in the market that can assist in killing the COVID-19 virus. However, many research firms and pharmaceutical manufacturers are increasingly investing in initiative to develop products that can effectively eliminate novel coronavirus.
The global gram-positive bacterial infections market has been segmented as follows:
Drug Type
- Antibiotic
- B-lactam
- Quinolones
- Macrolides
- Tetracyclines
- Aminoglycosides
- Sulfonamides
- Phenicols
- Others
- Antifungal
- Others (Antitoxins, Corticosteroids, Supplements, Anti-Dialectic)
Disease
- MRSA
- Pneumonia
- Sepsis
- Sinusitis
- Cellulitis
- Otitis
- Pharyngitis
- Impetigo
- Others (Anthrax, Erysipelothricosis, Necrotizing Fasciitis, Scarlet Fever, and Listeria)
Route of Administration
- Enteral
- Parenteral
- Others (Topical, Transdermal)
Distribution Channel
- Hospitals Pharmacies
- Drug Stores and Retail Pharmacies
- Others (Online Pharmacies, Mail Pharmacies, and Home Care Pharmacies)
Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111961/2900
